Brilinta’s label expansion for use beyond the first year will propel it ahead of rival oral antiplatelet inhibitors in ACS.
By Rajan Sharma, Senior Analyst
20 April 2016
I joined Datamonitor Healthcare in late in 2013 after completing a Masters in Pharmacology from the University of Oxford...
Read full bio
Uptake of AstraZeneca’s Brilinta (ticagrelor) is expected to be boosted by positive data from the PEGASUS-TIMI 54 Phase III trial, which supported a label expansion for the prolonged treatment of patients after a myocardial infarction beyond one year. Brilinta’s increased eligible patient population will propel it ahead of rivals such as Effient (prasugrel; Eli Lilly/Daiichi Sankyo), allowing it to become the most valuable oral antiplatelet brand by 2017. Data from the PEGASUS-TIMI 54 trial demonstrated that prolonged Brilinta treatment significantly reduced the risk of cardiovascular (CV) death, MI, or stroke compared to placebo. Datamonitor Healthcare anticipates these data and Brilinta’s subsequent label expansion will drive growth of the overall ACS market as treatment guidelines previously recommended use of platelet inhibitors for only one year after an initial event.
Brilinta sales for ACS in the US ($m), 2015–24
Source: Datamonitor Healthcare
This is excerpted from Datamonitor Healthcare’s Acute Coronary Syndrome: Forecast, which explores the impact of new and recently launched therapies on the highly genericized ACS market.
Get your free demo today – simply fill out the form to the right.